Ideaya Biosciences (IDYA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
7.0M
Operating Income
-327.0M
-4,671.07%
Net Income
-274.5M
-3,921.10%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
64.9M
Shareholders Equity
1.1B
Debt to Equity
0.06
Cash Flow Metrics
Operating Cash Flow
-229.0M
Free Cash Flow
-251.4M
Revenue & Profitability Trend
Ideaya Biosciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7.0M | 23.4M | 50.9M | 27.9M | 19.5M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 334.0M | 157.8M | 113.4M | 78.2M | 54.9M |
| Operating Income | -327.0M | -134.4M | -62.5M | -50.3M | -35.3M |
| Pre-tax Income | -274.5M | -113.0M | -58.7M | -49.8M | -34.5M |
| Income Tax | - | - | - | - | - |
| Net Income | -274.5M | -113.0M | -58.7M | -49.8M | -34.5M |
| EPS (Diluted) | - | -$1.96 | -$1.42 | -$1.41 | -$1.40 |
Income Statement Trend
Ideaya Biosciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 689.7M | 532.6M | 370.5M | 251.0M | 288.6M |
| Non-Current Assets | 434.4M | 116.7M | 17.5M | 130.4M | 9.7M |
| Total Assets | 1.1B | 649.3M | 388.0M | 381.3M | 298.3M |
| Liabilities | |||||
| Current Liabilities | 46.1M | 27.1M | 31.7M | 45.2M | 38.6M |
| Non-Current Liabilities | 18.9M | 1.1M | 6.8M | 34.7M | 61.4M |
| Total Liabilities | 64.9M | 28.2M | 38.5M | 79.8M | 100.0M |
| Equity | |||||
| Total Shareholders Equity | 1.1B | 621.1M | 349.5M | 301.5M | 198.3M |
Balance Sheet Composition
Ideaya Biosciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -274.5M | -113.0M | -58.7M | -49.8M | -34.5M |
| Operating Cash Flow | -229.0M | -103.3M | -87.5M | -60.3M | 52.4M |
| Investing Activities | |||||
| Capital Expenditures | -3.9M | -2.4M | -3.4M | -2.6M | -493.0K |
| Investing Cash Flow | -502.6M | -158.5M | -33.4M | -69.7M | -146.2M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 663.6M | 351.9M | 95.0M | 143.3M | 127.2M |
| Free Cash Flow | -251.4M | -117.6M | -90.6M | -58.4M | 55.0M |
Cash Flow Trend
Ideaya Biosciences Key Financial Ratios
Valuation Ratios
Forward P/E
-7.88
Price to Book
1.83
Price to Sales
268.00
PEG Ratio
-7.88
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-5,147.81%
Return on Equity
-31.34%
Return on Assets
-21.84%
Financial Health
Current Ratio
13.92
Debt to Equity
2.54
Beta
0.02
Per Share Data
EPS (TTM)
-$3.65
Book Value per Share
$11.70
Revenue per Share
$0.08
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| idya | 1.9B | - | 1.83 | -31.34% | 0.00% | 2.54 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.